Skip to main content
SpringerLink
Log in

Non-Hodgkin-Lymphome niedriger Malignität

  • Chapter
Therapiekonzepte Onkologie

Zusammenfassung

Gebräuchlichste histologische Klassifikation in Mitteleuropa ist bisher die auf zytologischen Kriterien beruhende Kiel-Klassifikation [86]. 1982 wurde versucht, mit der „Working Formulation“ [104] eine Vergleichbarkeit zu anderen Klassifikationen, z.B. der in den USA fr¨¹her weit verbreiteten Klassifikation von Rappaport [121] zu erreichen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Armitage JO (1993) Bone marrow transplantation for indolent lymphomas. Semin Oncol 20: 136–142

    PubMed  CAS  Google Scholar 

  2. Bagley CM, DeVita VT, Berard CW, Canellos GP (1972) Advanced lymphosarcoma: Intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisolone. Ann Intern Med 76: 227–234

    Article  PubMed  Google Scholar 

  3. Becker N, Frentzel-Beyme R, Wagner G (1984) Krebsatlas der Bundesrepublik Deutschland. Ed. 2nd Springer Verlag, Berlin Heidelberg New York Tokyo

    Google Scholar 

  4. Bergmann L, Fenchel K, Jahn B, Mitrou PS, Hoelzer D (1993) Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann Oncol 4: 371–375

    PubMed  CAS  Google Scholar 

  5. Bernhards J, Döhler U, Freund M, Rastetter J, Georgii A (1988) Die Bedeutung der Histopathologie des Knochenmarks für die Lebenserwartung von Patienten mit chronischer lymphatischer Leukämie. Med Klin 83: 637–642

    CAS  Google Scholar 

  6. Binet JL, Leporrier M, Dighiero G et al. (1977) A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer 40:855–864

    Article  PubMed  CAS  Google Scholar 

  7. Braverman JM, Yager NB, Chen M, Cadman EC, Hait WN, Maynard T (1987) Combined total body electron beam irradiation and chemotherapy for mycosis fungoides. J Am Acad Dermatol 16: 45

    Article  PubMed  CAS  Google Scholar 

  8. Brittinger G, Bartels H, Common H, Dühmke E, Engelhard M, Fülle HH, Gunzer U, Gyenes T, Heinz R, König E, Meusers P, Pralle H, Theml H, Zwingers T, Musshoff K, Stacher A, Brücher H, Herrmann F, Ludwig WD, Pribilla W, Burger-Schüler A, Löhr GW, Gremmel H, Oertel J, Gerhartz H, Köppen KM, Boll I, Huhn D, Binder T, Schoengen A, Nowicki L, Pees HW, Scheurlen PG, Leopold H, Wannenmacher M, Schmidt M, Löffler H, Michlmayr G, Thiel E, Zettel R, Rühl U, Wilke HJ, Schwarze EW, Stein H, Feller AC, Lennert K (1986) Klinische und prognostische Relevanz der Kiel-Klassifikation der Non-Hodgkin Lymphome. Onkologie 9: 118–125

    Article  PubMed  CAS  Google Scholar 

  9. Brittinger G, Bartels H, Common H, Dühmke E, Fülle HH, Gunzer U, Gyenes T, Heinz R, König E, Meusers P, Paukstat M, Pralle H, Theml H, Köpcke W, Thieme C, Zingers T, Musshoff K, Stacher A, Brücher H, Herrmann F, Ludwig WD, Pribella W, Burger-Schüler A, Löhr GW, Gremmel H, Oertel J, Gerhartz H, Koeppen K-M, Boll KM, Huhn D, Binder T, Schoengen A, Nowicki L, Pees WP, Scheurlen PG, Leopold H, Wannenmacher M, Schmidt M, Löffler H, Michlmayr G, Thiel E, Zettel R, Rühl U, Wilke HJ, Schwarze E-W, Stein H, Feller AC, Lennert K (1984) Clinical and prognostic relevance of the Kiel-classification of non-Hodgkin’s lymphomas: Results of a prospective multicenter study by the Kiel Lymphoma Study Group. Hematol Oncol 2: 269–306

    Article  PubMed  CAS  Google Scholar 

  10. Broder S, Bunn PA, Jaffe ES, Blattner W, Gallo RC, Wong-Staal F, Waldmann TA, DeVita VT (1984) T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med 100: 543–557

    Article  PubMed  CAS  Google Scholar 

  11. Bunn PA, Huberman MS, Whang-Peng J, Schechter GP, Guccion JG, Matthews MJ, Gaszar AF, Dunnick NR, Fischmann AB, Ihde DC, Cohen MH, Fossieck B, Minna JD (1980) Prospective staging evaluation of patients with cutaneous T-cell lymphomas. Ann Intern Med 93: 223–230

    Article  PubMed  Google Scholar 

  12. Bunn PA, Ihde DC, Foon KA (1986) The role of recombinant interferon alpha-2a in the therapy of cutaneous T-cell lymphomas. Cancer 57: 1689–1695

    Article  PubMed  Google Scholar 

  13. Burgers JM, Taal BG, Van Heerde P, Somers R, den Hartog Jager FC, Hart AA (1988) Treatment results of primary stage I and II non-Hodgkin’s lymphoma of the stomach. Radiother Oncol 11: 319–326

    Article  PubMed  CAS  Google Scholar 

  14. Canfield V, Baughman C, Vose J, Nichols C (1994) A phase II trial of 2-chlorodeoxyadenosine (2-CDA) in previously untreated patients with low grade non-Hodgkin’s lymphoma (NHL). Proc Am Soc Clin Oncol 13: 381 (Abstract)

    Google Scholar 

  15. Catovsky D (1982) Prolymphocytic leukemia. Nouv Rev Fr Hematol 24: 343–347

    PubMed  CAS  Google Scholar 

  16. Cavillin-Stahl E, Möller TR (1986) Prednimustine v cyclophosphamide-vincristine-prednisolone in the treatment of non-Hodgkin’s lymphoma with favorable histopathology: results of a national cancer care program in Sweden. Semin Oncol 13: 19–22

    Google Scholar 

  17. Cheson BD (1993) New chemotherapeutic agents for the treatment of low-grade non-Hodgkin’s lymphomas. Semin Oncol 20 (Suppl 5): 96–110

    PubMed  CAS  Google Scholar 

  18. Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA (1988) Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 29: 152–163

    Article  PubMed  CAS  Google Scholar 

  19. Cheson BD, Wittes RE, Friedman MA (1986) Low grade non-Hodgkin’s lymphomas revisited. Cancer Treat Rep 70: 1051–1054

    PubMed  CAS  Google Scholar 

  20. Chisesi T, Congiu M, Contu A, Coser P, Moretti L, Porcellini A, Rancan L, Salvagno L, Santini G, Vinante 0 (1991) Randomized study of chlorambucil (CB) compared to interferon (alfa-2b) combined with CB in low-grade non-Hodgkin’s lymphoma: an interim report of a randomized study. Eur J Cancer 27 (Suppl 4): S31–33

    Google Scholar 

  21. Chung HC, Roh JK, Koh EH, Kim JH, Hahn JS, Park IS, Min JS, Lee KS, Suh CO, Loh JJK, Kim BS (1990) Comparison of adjuvant radiotherapy and chemotherapy following surgery in stage IE and IIE primary gastrointestinal tract non-Hodgkin’s lymphoma. Yonsei Med J 31: 144–155

    PubMed  CAS  Google Scholar 

  22. Coiffier B, Bastion Y, Berger F, Felman P, Bryon PA (1993) Prognostic factors in follicular lymphomas. Semin Oncol 20 (Suppl 5): 89–95

    PubMed  CAS  Google Scholar 

  23. Covelli A, Papa G, Vegna ML, Coppola G, De Pità O, Puddu P, Simoni R, Criscuolo D (1989) Recombinant alpha-2a interferon (IFN) as initial therapy in mycosis fungoides (MF): Results of a 3-year follow-up. Proc Am Soc Clin Oncol 8: 251 (Abstract)

    Google Scholar 

  24. Dana BW, Dahlberg S, Nathwani BN, Chase E, Coltman C, Miller TP, Fisher RI (1993) Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol 11: 644–651

    PubMed  CAS  Google Scholar 

  25. Dawson IMP, Cornes JS, Morson BC (1961) Primary malignant lymphoid tumors of the intestinal tract. Br J Surg 49: 80–89

    Article  PubMed  CAS  Google Scholar 

  26. DeVita VT, Hellman S, Rosenberg SA (1989) Cancer. Principles and practice of oncology. Ed. 3rd J.B. Lippincott, Philadelphia

    Google Scholar 

  27. Döhner H, Ho AD, Thaler J, Stryckmans P, Sonneveld P, De Witte T, Lechner K, Lauria F, Bödewaldt-Radzun S, Suciu S, Solbu G, Witt B, Hunstein W, Zittoun R (1993) Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst 85: 658–662

    Article  PubMed  Google Scholar 

  28. Dragosics B, Bauer P, Radaszkiewicz T (1985) Primary gastrointestinal non-Hodgkin’s lymphomas. A retrospective clinicopathologic study of 150 cases. Cancer 55: 1060–1073

    Article  PubMed  CAS  Google Scholar 

  29. Feil W, Wenzel E, Radaskiewicz T, Schiessel R (1987) Das Non-HodgkinLymphom des Magens: Chirurgische Therapie and Prognose. Wien Klin Wochenschr 99: 426–430

    PubMed  CAS  Google Scholar 

  30. Fleming ID, Mitchell S, Dilawari RA (1982) The role of surgery in the management of gastric lymphoma. Cancer 49: 1135–1141

    Article  PubMed  CAS  Google Scholar 

  31. Foss Abrahamsen A, Lenner P, Hedenus M, Landys K, Noppa H (1987) Mitoxantrone in the treatment of patients with non-Hodgkin’s Lymphoma. Cancer Treat Rep 71: 1209–1212

    Google Scholar 

  32. Foss F, Fischmann A, Schechter G, Ihde B, Breneman D, Breneman J, Anderson M, Eddy J, Sausville E (1989) Phase II trial of pentostatin and interferon alpha-2a in advanced mycosis fungoides/Sézary syndrome (MF/SS). Proc Am Soc Clin Oncol 8: 276 (Abstract)

    Google Scholar 

  33. Francica G, Cozzolino G, Morante R, Martinelli G, Cigolari S, Dionisio M, Romano V, Schiavone M, Sperandeo M, Cacciatore L (1990) Gastric lymphoma: diagnosis and follow-up of chemotherapy-induced changes using real-time ultrasonography: a report of three cases. Eur J Radiol 11: 68–72

    Article  PubMed  CAS  Google Scholar 

  34. Franssila KO, Jaser N, Sivula A (1993) Gastrointestinal non-Hodgkin’s lymphoma. A population-based clinicopathological study of 111 adult cases with a follow-up of 10–15 years. APMIS 101: 631–641

    Article  PubMed  CAS  Google Scholar 

  35. Freedman AS, Nadler LM (1993) Which patients with relapsed non-Hodgkin’s lymphoma benefit from high-dose therapy and hematopoietic stem-cell transplantation? [editorial; comment]. J Clin Oncol 11: 1841–1843

    PubMed  CAS  Google Scholar 

  36. French COOP Group on CLL (1986) Effectiveness of „CHOP“ regimen on advanced untreated chronic lymphocytic leukemia. Lancet i:1346–1349

    Google Scholar 

  37. French COOP Group on CLL (1989) Long-term results of the CHOP regimen in stage C chronic lymphocytic leukemia. Br J Haematol 73: 334–340

    Article  Google Scholar 

  38. French COOP Group on CLL (1990) A randomized clinical trial of chlorambucil versus COP in stage B chronic lymphocytic leukemia. Blood 75: 1422–1425

    Google Scholar 

  39. French COOP Group on CLL (1990) Effects of chlorambucil and therapeutic decision in initial forms of chronic lymphocytic leukemia (stage A): results of a randomized clinical trial in 612 patients. Blood 75: 1414–1421

    Google Scholar 

  40. French COOP Group on CLL (1993) Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, andcyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: preliminary results of a controlled clinical trial. Semin Oncol 20: 21–23

    Google Scholar 

  41. Freund M, Hanauske A-R (1990) Interferon alpha in der Therapie der NonHodgkin-Lymphome. Onkologie 13: 424–428

    Article  PubMed  CAS  Google Scholar 

  42. Friedenberg WR, Anderson J, Wolf BC, Cassileth PA, Oken MM (1993) Modified vincristine, doxorubicin, and dexamethasone regimen in the treatment of resistant or relapsed chronic lymphocytic leukemia. An Eastern Cooperative Oncology Group study. Cancer 71: 2983–2989

    Article  PubMed  CAS  Google Scholar 

  43. Gale RP, Foon KA (1987) Biology of chronic lymphocytic leukemia. Semin Hematol 24: 209–229

    PubMed  CAS  Google Scholar 

  44. Garvin Ai, Simon RM, Osborne CK, Merrill J, Young RC, Berard CW (1993) An autopsy study of histologic progression in non-Hodgkin’s lymphoma: 192 cases from the National Cancer Institute. Cancer 52: 393

    Google Scholar 

  45. Glatstein E, Donaldson SS, Rosenberg SA, Kaplan HS (1977) Combined modality therapy in malignant lymphoma. Cancer Treat Rep 61: 11199–11207

    Google Scholar 

  46. Glatstein E, Fuks Z, Goffinet DR et al. (1976) Non-Hodgkin’s lymphoma of stage III extent. Is total lymphoid irradiation appropriate treatment? Cancer 37: 2806

    Article  PubMed  CAS  Google Scholar 

  47. Gobbi PG, Dionigi P, Barbieri F, Corbella F, Bertoloni D, Grignani G, Jemos V, Pieresca C, Ascari E (1990) The role of surgery in the multimodal treatment of primary gastric non-Hodgkin’s lymphomas. A report of 76 cases and review of the literature. Cancer 65: 2528–2536

    Article  PubMed  CAS  Google Scholar 

  48. Golomb HM, Fefer A, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Ratain MJ, Thompson J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW (1988) Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. Semin Oncol 15 (Suppl 5): 7–9

    PubMed  CAS  Google Scholar 

  49. Golomb HM, Ratain MJ, Fefer A, Thompson J, Golde DW, Ozer H, Portlock C, Silber R, Rappeport J, Bonnem E, Spiegel R, Tensen L, Burke JS, Vardiman JW (1988) Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. J Natl Cancer Inst 80: 369–373

    Article  PubMed  CAS  Google Scholar 

  50. Gospodarowicz MK, Bush RS, Brown TC, Chua T (1983) Curability of gastrointestinal lymphoma with combined surgery and radiation. Int J Radiat Oncol Biol Phys 9: 3–9

    Article  PubMed  CAS  Google Scholar 

  51. Gospodarowicz MK, Bush RS, Brown TC, Chua T (1984) Prognostic factors in nodular lymphomas. Int J Radiat Oncol Biol Phys 10: 489–497

    Article  PubMed  CAS  Google Scholar 

  52. Greco FA, Johnson DH, Hainsworth JD (1991) Chronic oral etoposide. Cancer 67: 303–309

    Article  PubMed  CAS  Google Scholar 

  53. Grever M, Kopecky K, Head D, Cassileth P, Golomb H, Habermann T, Rai K, Eisenhauer E, Cheson B (1992) A randomized comparison of deoxycoformicin (DCF) versus alfa-2a interferon (IFN) in previously untreated patients with hairy cell leukemia (HCL): An NCI-sponsored Intergroup Study (SWOG, ECOG, CALGB, NCIC CTG). Proc Am Soc Clin Oncol 1164: 264 (Abstract)

    Google Scholar 

  54. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM (1991) Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 325: 1525–1533

    Article  PubMed  CAS  Google Scholar 

  55. Griem ML, Tokas RP, Petras V et al. (1979) Combined therapy for patients with mycosis fungoides. Cancer Treat Rep 63: 655

    PubMed  CAS  Google Scholar 

  56. Hagenbeek A, Carde P, Sommer P, Thomas J, de Bock R, Raemaekers J, van Hoof A, Van Glabbeke M, Meerwaldt JH (1992) Maintenance of remission with human recombinant alpha-2 interferon (Roferon A) in patients with stages III and IV low grade malignant non-Hodgkin’s lymphoma. Results from a prospective, randomized phase III clinical trial in 331 patients. Blood 80 (Suppl I): 74a (Abstract)

    Google Scholar 

  57. Hakimian D, Tallman MS, Kiley C, Peterson L (1993) Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell leukemia. Blood 82: 1798–1802

    PubMed  CAS  Google Scholar 

  58. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JKC, Cleary ML, Delsol G, De WolfPeeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Müller-Hermelink HK, Pileri SA, Piris MA, Ralfkiaer E, Warnke RA (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84: 1361–1392

    PubMed  CAS  Google Scholar 

  59. Heim ME, Fritze D, Ho AD, Mebes W, Abel U (1987) Phase-III-Studie zur Chemotherapie niedrig-maligner Non-Hodgkin-Lymphome: Vergleich einer Vincristin-mit einer Vindesin-Kombinations-Chemotherapie. Onkologie 10, 345–348

    Article  PubMed  CAS  Google Scholar 

  60. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L (1980) Gastrointestinal involvement in non-Hodgkin’s lymphoma. Cancer 46: 215–222

    Article  PubMed  CAS  Google Scholar 

  61. Hiddemann W, Rottmann R, Wörmann B, Thiel E, Essinck M, Ottensweiler C, Freund M, Büchner T, van de Loo J (1991) Treatment of advanced chronic lymphocytic leukemia by fludarabine. Results of a clinical phase-II study. Ann Hematol 63: 1–4

    Article  PubMed  CAS  Google Scholar 

  62. Hiddemann W, Unterhalt M, Koch P, Nahler M, van de Loo J (1990) Treatment of low-grade non-Hodgkin’s lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study. Semin Oncol 17: 20–23

    PubMed  CAS  Google Scholar 

  63. Hiddemann W, Unterhalt M, Pott C, Wörmann B, Sandford D, Freund M, Engert A, Gassmann W, Holtkamp W, Seufert M, Hellriegel K, Knauf B, Emmerich B, Kanz L, Koch P (1993) Fludarabine single-agent therapy for relapsed low-grade non-Hodgkin’s lymphomas: a phase II study of the German low-grade non-Hodgkin’s lymphoma study group. Semin Oncol 20: 28–31

    PubMed  CAS  Google Scholar 

  64. Ho AD, del Valle F, Rückle H, Schwammborn J, Schlimok G, Hiddemann W, Meusers P, Thiel E, Dörken B, Hunstein W (1989) Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin’s lymphoma. Cancer 64: 1388–1392

    Article  PubMed  CAS  Google Scholar 

  65. Ho AD, Thaler J, Mandelli F, Lauria F, Zittoun R, Willemze R, Mc Vie G, Marmont AM, Prümmer O, Stryckmans P, Witt B, Suciu S, Solbu G, De Witte T, BödewadtRadzun S (1989) Response to pentostatin in hairy-cell leukemia refractory to interferon-alpha. J Clin Oncol 7: 1533–1538

    PubMed  CAS  Google Scholar 

  66. Hochster H, Cassileth P (1990) Fludarabine phosphate therapy of non-Hodgkin’s lymphoma. Semin Oncol 17: 63–65

    PubMed  CAS  Google Scholar 

  67. Hoppe RT (1985) The role of radiation therapy in the management of non-Hodgkin’s lymphomas. Cancer 55: 2176–2183

    Article  PubMed  CAS  Google Scholar 

  68. Horning SJ (1993) Natural history of and therapy for the indolent non-Hodgkin’s lymphomas. Semin Oncol 20: 75–88

    PubMed  CAS  Google Scholar 

  69. Horstmann M, Erttmann R, Winkler K (1994) Relapse of MALT lymphoma associated with helicobacter pylori after antibiotic treatment. Lancet 343: 1098–1099

    Article  PubMed  CAS  Google Scholar 

  70. Isonaki HA, Hakuhuen T, Joutseulahti U (1978) Excess risk of lymphoma, leukemia, and myeloma in patients with rheumatoid arthritis. J Chron Dis 31: 691

    Article  Google Scholar 

  71. Johnston JB, Eisenhauer E, Corbett WEN, Scott JG, Zaentz SD (1988) Efficacy of 2’-dexycoformycin in hairy-cell leukemia: A study of the National Cancer Institute and of Canada Clinical Trials Group. JNCI 80: 765–769

    Article  PubMed  CAS  Google Scholar 

  72. Juliusson G, Liliemark J (1993) High complete remission rate from 2-chloro-2’deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 11: 679–689

    PubMed  CAS  Google Scholar 

  73. Kantarjian HM, Alexanian R, Koller CA, Kurzrock R, Keating MJ (1990) Fludarabine therapy in macroglobulinemic lymphoma. Blood 75: 1928–1931

    PubMed  CAS  Google Scholar 

  74. Kantarjian HM, Redman JR, Keating MJ (1990) Fludarabine phosphate therapy in other lymphoid malignancies. Semin Oncol 17: 66–70

    PubMed  CAS  Google Scholar 

  75. Keating MJ, O’Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H (1994) Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol 31: 28–39

    PubMed  CAS  Google Scholar 

  76. Kemena A, O’Brien S, Kantarjian H, Robertson L, Koller C, Beran M, Estey E, Plunkett W, Lerner S, Keating MJ (1993) Phase II clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymphoma 10: 187–193

    Article  PubMed  CAS  Google Scholar 

  77. Khan A, Schiller G, Levine A, Harvey L, Lee M, Espina B, Boswell W, Enny C, Nathwani B (1994) 2’-Chloro-2’-deoxyadenosine (2-CDA), an active agent in the treatment of advanced relapsed or refractory low to intermediate grade non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol 13:386 (Abstract)

    Google Scholar 

  78. Khouri IF, Keating MJ, Vriesendorp HM, Reading CL, Przepiorka D, Huh YO, Andersson BS, van Besien KW, Mehra RC, Giralt SA et al. (1994) Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol 12: 748–758

    PubMed  CAS  Google Scholar 

  79. Kinlen LJ, Sheil AGR, Peto J, Doll R (1979) Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 7: 146

    Google Scholar 

  80. Knospe WH (1974) Bi-weekly chlorambucil treatment of CLL. Cancer 33: 555–562

    Article  PubMed  CAS  Google Scholar 

  81. König E, Meusers P, Brittinger G (1979) Efficacy of doxorubicin in prolymphocytic leukemia. Br J Haematol 42: 487–488

    Article  PubMed  Google Scholar 

  82. Kraut EH, Bouroncle BA, Grever MR (1989) Pentostatin in the treatment of advanced hairy cell leukemia. J Clin Oncol 7: 168–172

    PubMed  CAS  Google Scholar 

  83. Landys KE (1988) Mitoxatrone in combination with prednimustine in treatment of unfavourable non-Hodgkin’s lymphoma. Invest New Drugs 6: 105–113

    Article  PubMed  CAS  Google Scholar 

  84. Lauria F, Rondelli D, Raspadori D, Benfenati D, Tura S (1994) Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Eur J Haematol 52: 16–20

    Article  PubMed  CAS  Google Scholar 

  85. Leiby JM, Snider KM, Kraut EH et al. (1987) A phase II trial of 9-/3-D-arabinofuranosyl-2-fluoroadenine 5’monophosphate in non-Hodgkin’s lymphoma: Prospective comparison of response with deoxycytidine kinase activity. Cancer Res 47: 2719–2722

    PubMed  CAS  Google Scholar 

  86. Lennert K, Feller A (1990) Histopathologie der Non-Hodgkin-Lymphome (nach der aktualisierten Kiel-Klassifikation). Ed. 2nd Springer Verlag, Berlin

    Google Scholar 

  87. Levey IL (1987) Angioimmunoblastic lymphadenopathy: Comprehensive review: Cancer Invest 5: 633–647

    Article  PubMed  CAS  Google Scholar 

  88. Levine AM (1987) Non-Hodgkin’s lymphomas and other malignancies in the acquired immune deficiency syndrome. Semin Oncol 14 (Suppl 3): 34–39

    PubMed  CAS  Google Scholar 

  89. Levitt SH, Bloomfield CD, Lee CKK, Nesbitt ME, McKenna RW (1976) Extended field radiotherapy in non-Hodgkin’s lymphomas. Radiology 118: 457–459

    PubMed  CAS  Google Scholar 

  90. Lewin KJ, Ranchod M, Dorman RF (1978) Lymphomas of the gastrointestinal tract. Cancer 42: 693–707

    Article  PubMed  CAS  Google Scholar 

  91. Liepman M, Votaw ML (1978) The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer 41: 1664–1669

    Article  PubMed  CAS  Google Scholar 

  92. Lister TA, Cullen MH, Beard MEJ, Brearley RL, Whitehouse JMA, Wrigley PFM, Stansfeld AG, Sutcliffe SBJ, Malpas JS, Crowther D (1978) Comparison of combined and single-agent chemotherapy in non-Hodgkin’s lymphoma of favourable type. Br Med J 1: 533

    Article  PubMed  CAS  Google Scholar 

  93. Maor MH, Maddux B, Osborne BM, Fuller LM, Sullivan JA, Nelson RS, Martin RG, Libshitz HI, Velasquez WS, Bennet RW (1984) Stages IE and IIE non-Hodgkin’s lymphoma of the stomach: comparison of treatment modalities. Cancer 54: 2330–2337

    Article  PubMed  CAS  Google Scholar 

  94. Maor MH, Velasquez WS, Fuller LM, Silvermintz KB (1990) Stomach conservation in stages IE and IIE gastric non-Hodgkin’s lymphoma [see comments]. J Clin Oncol 8: 266–271

    PubMed  CAS  Google Scholar 

  95. McLaughlin P, Cabanillas F, Hagemeister FB, Swan F Jr, Romaguera JE, Taylor S, Rodriguez MA, Velasquez WS, Redman JR, Gutterman JU (1993) CHOP-Bleo plus interferon for stage IV low-grade lymphoma. Ann Oncol 4: 205–211

    PubMed  CAS  Google Scholar 

  96. McLaughlin P, Hagemeister FB, Sarris A, Romaguera J, Pate O, Younes A, Swan F, Moore D, Cabanillas F (1994) Fludarabine, mitoxantrone, and dexamethasone (FND) for recurrent low grade lymphoma (LGL): a phase II trial. Proc Am Soc Clin Oncol 13: 387 (Abstract)

    Google Scholar 

  97. McSweeney EN, Giles FJ, Worman CP, Jewel AP, Tsakona CP, Hoffbrand AV, Mehta AB, Newland AC, Cawley JC, Galvani D et al. (1993) Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia. Br J Haematol 85: 77–83

    Article  PubMed  CAS  Google Scholar 

  98. Meusers P, Barthels H, Binder T, Engelhard M, Fülle HH, Gunzer U, Havemann K, König E, König HJ, Kuse R, Löffler H, Ludwig WD, Pezzuto A, Pralle H, Schoppe WD, Theml H, Zurborn KH, Zwingers T, Lennert K, Brittinger G (1986) Zur Therapie des zentrozytischen Lymphoms — Ergebnisse einer multizentrischen prospektiven randomisierten Studie (COP v s. CHOP-Schema). Klin Wschr 64 Suppl V: 105

    Google Scholar 

  99. Monserrat E, Alcala A, Parody R, Domingo A, Garcia-Conde J, Bueno J, Ferran C, Sanz MA, Giralt M, Rubio D, Anton I, Estapé J, Rozman C (1985) Treatment of chronic lymphocytic leukemia in advanced stages. A randomized trial comparing chlorambucil plus prednisone versus cyclophosphamide, vincristine and prednisone. Cancer 56: 2369–2375

    Article  Google Scholar 

  100. Moormeier JA, Ratain MJ, Westbrook CA, Vardiman JW, Daly KM, Golomb HM (1989) Low-dose interferon alfa-2b in the treatment of hairy cell leukemia. JNCI 81: 1172–1174

    Article  PubMed  CAS  Google Scholar 

  101. Musshoff K, Schmidt-Vollmer H (1975) Prognosis of non-Hodgkin’s lymphomas with special emphasis on the staging classification. Z Krebsforsch 83: 323–341

    Article  CAS  Google Scholar 

  102. Nielsen B, Braide I (1992) Three years’ continuous low-dose interferon-alpa treatment of hairy-cell leukemia: Evaluation of response and maintenance dose. Eur J Haematol 49: 174–179

    Article  PubMed  CAS  Google Scholar 

  103. Nissen NI, Hansen SW (1990) High activity of daily-schedule mitoxantrone in newly diagnosed low-grade non-Hodgkin’s lymphomas: a 5-year follow-up. Semin Oncol 17: 10–12

    PubMed  CAS  Google Scholar 

  104. Non-Hodgkin’s Lymphoma Pathologic Classification Project (1982) National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. Cancer 49: 2112–2135

    Article  Google Scholar 

  105. O’Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M (1993) Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 82: 1695–1700

    PubMed  Google Scholar 

  106. Okazaki K et al. (1994) Gene rearrangements, helicobacter pylori, and gastric MALT lymphoma. Lancet 343: 1636

    Article  PubMed  CAS  Google Scholar 

  107. Parayani SB, Hoppe RT, Cox RS, Colby TV, Rosenberg SA, Kaplan HS (1983) Analysis of non-Hodgkin’s lymphomas with nodular and favourable histologies, stages I and II. Cancer 52: 2300–2307

    Article  Google Scholar 

  108. Parkinson DR, Sznol M, Cheson BD (1993) Biologic therapies for low-grade lymphomas. Semin Oncol 20: 111–117

    PubMed  CAS  Google Scholar 

  109. Parsonet J et al. (1994) Helicobacter pylori infection and gastric lymphoma. N Engl J Med 330: 1267–1271

    Article  Google Scholar 

  110. Paryani SB, Hoppe RT, Cox RS, Colby TV, Kaplan HS (1984) The role of radiation therapy in the management of stage III follicular lymphoma. J Clin Oncol 2: 841

    PubMed  CAS  Google Scholar 

  111. Pedersen-Bjergard J, Mork Hansen J, Geisler CH, Nissen NI (1980) Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin’s lymphomata and chronic lymphocytic leukemia previously treated with steroids and alkylating agents. Acta Med Scand 207: 215

    Article  Google Scholar 

  112. Peterson BA, Petroni G, Oken MM, Ozer H (1993) Cyclophosphamide versus cyclophosphamide plus interferon alfa-2b in follicular low grade lymphomas: a preliminary report of an intergroup trial (CALGB 8691 and EST 7486). Proc Am Soc Clin Oncol 12: 366 (Abstract)

    Google Scholar 

  113. Pigaditou A, Rohatiner AZ, Whelan JS, Johnson PW, Ganjoo RK, Rossi A, Norton AJ, Amess J, Lim J, Lister TA (1993) Fludarabine in low-grade lymphoma Semin Oncol 20: 24–27

    PubMed  CAS  Google Scholar 

  114. Piro LD, Carrera CJ, Beutler E, Carson DA (1988) 2-Chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72: 1069–1073

    Google Scholar 

  115. Piro LD, Saven A, Ellison E, Thurston D, Carrera CJ, Carson DA, Beutler E (1992) Prolonged complete remissons following 2-chlorodeoxyadenosine (2-CDA) in hairy cell leukemia (HCL). Proc Am Soc Clin Oncol 11: 258 (Abstract)

    Google Scholar 

  116. Portlock CS, Rosenberg SA (1979) No initial therapy for stage III and IV non-Hodgkin’s lymphoma of favourable histologic types. Ann Intern Med 90: 10–13

    Article  PubMed  CAS  Google Scholar 

  117. Price CG, Rohatiner AZ, Steward W, Deakin D, Bailey N, Norton A, Blackledge G, Crowther D, Lister TA (1991) Interferon alfa-2b in addition to chlorambucil in the treatment of follicular lymphoma: preliminary results of a randomized trial in progress. Eur J Cancer 27 Suppl 4: S34–S36

    Google Scholar 

  118. Pussio CA, Mittelman A, Lichtman SM et al. (1991) A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia. J Clin Oncol 9: 1562–1569

    Google Scholar 

  119. Quesada JR, Reuben J, Manning JT, Hersh EM, Gutterman JU (1984) Alpha interferon for induction of remission in hairy-cell leukemia. N Engl J Med 310: 15–18

    Article  PubMed  CAS  Google Scholar 

  120. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS (1974) Clinical staging of chronic lymphocytic leukemia. Blood 43: 789–795

    Google Scholar 

  121. Rappaport H (1966) Tumors of the hematopoietic system. Armed Forces Institute of Pathology, Washington, DC

    Google Scholar 

  122. Robertson LE, Hall R, Keating MJ, Estey E, Kantarjian HM, McLaughlin P, Hagemeister FB, Plunkett W (1993) High-dose cytosine arabinoside in chronic lymphocytic leukemia: a clinical and pharmacologic analysis. Leuk Lymphoma 10:43–48

    Google Scholar 

  123. Robertson LE, O’Brien S, Koller C, Beran M, Feldman E, Kantarjian H, Hagemeister F, Andreeff M, Lerner S, Plunkett W, Keating MJ (1992) A three-day schedule of fludarabine in chronic lymphocytic leukemia (CLL). Blood 80 (Suppl 1): 47a (Abstract)

    Google Scholar 

  124. Robertson LE, Pugh W, O’Brien S, Kantarjian H, Hirsch Ginsberg C, Cork A, McLaughlin P, Cabanillas F, Keating MJ (1993) Richter’s syndrome: a report on 39 patients. J Clin Oncol 11: 1985–1989

    PubMed  CAS  Google Scholar 

  125. Rosenberg SA (1985) The low grade Non-Hodgkin’s lymphomas. Challenges and opportunities. J Clin Oncol 3: 299–310

    PubMed  CAS  Google Scholar 

  126. Saven A, Piro LD (1993) Complete remissions in hairy cell leukemia with 2-chlorodeoxyadenosine after failure with 2’-deoxycoformycin. Ann Intern Med 119: 278–283

    Article  PubMed  CAS  Google Scholar 

  127. Schwarze EW (1983) Primär extranodale Non-Hodgkin-Lymphome: Ihre Histologie, bevorzugte Lokalisation, Häufigkeit and Pathogenese. In: Diehl V, Sack H (eds) Diagnostik and Therapie der Non-Hodgkin-Lymphome. Zuckschwert, Muenchen, Bern, Wien, pp 131–137

    Google Scholar 

  128. Shiu MH, Karas M, Nisce L, Burton L, Filips D, Liebermann P (1982) Management of primary gastric lymphoma. Ann Surg 195: 196–202

    Article  PubMed  CAS  Google Scholar 

  129. Sibbald R, Catovsky D (1979) Complete remission in prolymphocytic leukaemia with the combination chemotherapy. Br J Haematol 42: 488–490

    Article  PubMed  CAS  Google Scholar 

  130. Siegert W, Agthe A et al, Grieser H, Schwerdtfeger R, Brittinger G, Engelhard M, Kuse R, Tiemann M, Lennert K, Huhn D (1992) Treatment of angioimmunoblastic lymphadenopathy (AILD)-type T-cell lymphoma using prednisone with or without the COP/BLAM/IMVP-16 regimen. Ann Intern Med 117: 364–370

    Article  PubMed  CAS  Google Scholar 

  131. Siegert W, Nerl C, Meuthen I, Zahn T, Brack N, Lennert K, Huhn D (1991) Recombinant human interferon-alpha in the treatment of angioimm unoblastic lymphadenopathy: results in 12 patients. Leukemia 5: 892–895

    PubMed  CAS  Google Scholar 

  132. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O’Connell MJ, Oken M, Borden E (1992) Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin’s lymphoma. N Engl J Med 327: 1336–1341

    Article  PubMed  CAS  Google Scholar 

  133. Smith II JW, Longo DL, URba WJ, Clark JW, Watson T, Beveridge J, Conlon KC, Sznol M, Creekmore SP, Alvord WG, Lawrence JB, Steis RG (1991) Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-a2a. Blood 78: 1664–1671

    PubMed  Google Scholar 

  134. Solal-Celigny P, Lepage E, Brousse N, Reyes F, Haioun C, Leporrier M, Peuchmaur M, Bosly A, Parlier Y, Brice P, Coiffier B, Gisselbrecht C, for the Groupe D’Etude des Lymphomes de L’Adulte (1993) Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 329: 1608–1614

    Article  Google Scholar 

  135. Spiers ASD, Moore D et al, Cassileth PA, Harrington DP, Cummings FJ, Neiman RS, Bennett JM, O’Connell MJ (1987) Remissions in hairy-cell leukemia with pentostatin (2’-deoxycoformicin). N Engl J Med 316: 825–830

    Article  PubMed  CAS  Google Scholar 

  136. Steinke B, Waller HD (1987) Zur klinischen Relevanz von Laborparametern bei malignen Non-Hodgkin-Lymphomen — eine retrospektive Analyse. Lab Med 11: 69–74

    Google Scholar 

  137. Stolte M, Eidt S (1993) Healing gastric MALT lymphomas by eradicating H pylori? Lancet 342: 568

    Article  PubMed  CAS  Google Scholar 

  138. Taal BG, Den Hartog Jager FCA, Burgers JMV, Van Heerde P, Tio TL (1989) Primary non-Hodgkin’s lymphoma of the stomach: Changing aspects and therapeutic choices. Eur J Cancer Clin Oncol 25: 439–450

    Article  PubMed  CAS  Google Scholar 

  139. Taylor HG, Butler WM, Rhoads J, Karscher DS, Detrick-Hooks B (1982) Prolymphocytic leukemia: treatment with combination chemotherapy to include doxorubicin. Cancer 49: 1524–1529

    Article  PubMed  CAS  Google Scholar 

  140. Thaler J, Grunewald K, Gattringer C, Ho AD, Weyrer K, Dietze O, Stauder R, Fluckinger T, Lang A, Huber H (1993) Long-term follow-up of patients with hairy cell leukaemia trated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration. Br J Haematol 84: 75–82

    Article  PubMed  CAS  Google Scholar 

  141. Thompson JA, Kidd P, Rubin E, Fefer A (1989) Very low dose a-2b interferon for the treatment of hairy cell leukemia. Blood 73: 1440–1443

    PubMed  CAS  Google Scholar 

  142. Tondini C, Giardini R, Bozzetti F, Valagussa P, Santoro A, Bertulli R, Balzarotti M, Rocca A, Lombardi F, Ferreri AJ et al. (1993) Combined modality treatment for primary gastrointestinal non-Hodgkin’s lymphoma: the Milan Cancer Institute experience [see comments]. Ann Oncol 4: 831–837

    PubMed  CAS  Google Scholar 

  143. Volk JR, Kjieldsberg CR, Eyre HJ, Marty J (1983) T-cell prolymphocytic leukemia. Clinical and immunological characterization. Cancer 52: 2049–2054

    Article  PubMed  CAS  Google Scholar 

  144. Von Hoff D, Dahlberg S, Hartsock R (1989) Evaluation of fludarabine mono-phosphate in patients with advanced mycosis fungides: A Southwest Oncology Group study. Proc Am Soc Clin Oncol 8: 269 (Abstract)

    Google Scholar 

  145. Watanabe S, Sato Y, Shimoyama M, Minato K, Shimosato Y (1986) Immunoblastic lymphadenopathy, angioimmunoblastic lymphadenopathy, and IBL-like T-cell lymphomas. A spectrum of T-cell neoplasia. Cancer 58: 2224–2232

    Article  PubMed  CAS  Google Scholar 

  146. Weingrad DN, Decosse JJ, Sherlock P, Straus D, Lieberman PH, Filippa DA (1982) Primary gastrointestinal lymphoma. A 30-year review. Cancer 49: 1258–1265

    Article  PubMed  CAS  Google Scholar 

  147. Whelan JS, Davis CL, Rule S, Ransson M, Smith OP, Mehta AB, Catovsky D, Rohatiner AZ, Lister TA (1991) Fludarabine phosphate for the treatment of low grade lymphoid malignancy. Br J Cancer 64: 120–123

    Article  PubMed  CAS  Google Scholar 

  148. Wijermans PW, Gerrits WB, Haak HL (1993) Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol 50: 292–296

    Article  PubMed  CAS  Google Scholar 

  149. Winkler CF, Sausville EA, Ihde DC, Fischmann AB, Schechter GP, Kumar PP, Nibhanubdi JR, Minna JD, Mauch RW, Eddy UL et al. (1986) Combined modality treatment of cutaneous T cell lymphomas: Results of 6 year follow-up. J Clin Oncol 4: 1094

    PubMed  CAS  Google Scholar 

  150. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG (1993) Regression of primary low-grade B-cell gastric lymphoma of mucosaassociated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342: 575–577

    Article  PubMed  CAS  Google Scholar 

  151. Yahalom J, Varsos G, Fuks Z, Myers J, Clarkson BD, Straus DJ (1993) Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 71: 2342–2350

    Article  PubMed  CAS  Google Scholar 

  152. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita VT Jr (1988) The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 25: 11–16

    PubMed  CAS  Google Scholar 

  153. Zakem MH, Davis BR, Adelstein DJ, Hines JD (1987) Treatment of advanced sage mycosis fungoides with bleomycin, doxorubicin, and methotrexate with nitrogen mustard (BAM-M). Cancer 58: 2611

    Article  Google Scholar 

  154. Zinzani PL, Lauria F, Rondelli D, Benefenati D, Raspadori D, Bocchia M, Gozzetti A, Cavo M, Cirio TM, Zaja F et al. (1993) Fludarabine in patients with advanced and/or resistant B-chronic lymphocytic leukemia. Eur J Haematol 51: 93–97

    Article  PubMed  CAS  Google Scholar 

  155. Zinzani PL, Lauria F, Rondelli D, Benefenati D, Raspadori D, Bocchia M, Bendandi M, Gozzetti A, Zaja F, Fanin R et al. (1993) Fludarabine: an active agent in the treatment of previously-treated and untreated low-grade non-Hodgkin’s lymphoma. Ann Oncol 4: 575–578

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. M. Freund
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Heußner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung) Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Freund, M., Heußner, P. (1995). Non-Hodgkin-Lymphome niedriger Malignität. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10494-1_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10494-1_10

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-58586-2

  • Online ISBN: 978-3-662-10494-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation